![](https://webarchive.library.unt.edu/eot2008/20081005084250im_/http://www.nci.nih.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20081005084250im_/http://www.nci.nih.gov/images/spacer.gif)
NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine A cancer vaccine containing HLA class I- and II-binding peptides derived from the NY-ESO-1/LAGE-1 cancer/testis antigen with potential immunostimulatory and antineoplastic activities. Upon administration, NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine may induce a cytotoxic immune response against tumor cells that over-express NY-ESO-1/LAGE-1.
Rarely expressed by normal cells, the NY-ESO-1/LAGE-1 cancer/testis antigen has been shown to be preferentially expressed on the surface of some cancer cell types. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20081005084250im_/http://www.nci.nih.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081005084250im_/http://www.nci.nih.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081005084250im_/http://www.nci.nih.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081005084250im_/http://www.nci.nih.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081005084250im_/http://www.nci.nih.gov/images/spacer.gif) |